# Effects of Immulina TM Supplements With PASC Patients

> **NCT05524532** · PHASE3 · COMPLETED · sponsor: **University of Mississippi Medical Center** · enrollment: 101 (actual)

## Conditions studied

- Post Acute COVID-19 Syndrome

## Interventions

- **DRUG:** Immulina TM
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT05524532
- **Lead sponsor:** University of Mississippi Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-20
- **Primary completion:** 2025-07-29
- **Final completion:** 2025-07-29
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05524532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05524532, "Effects of Immulina TM Supplements With PASC Patients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05524532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*